Trial Profile
An Open Label Fixed Sequence Phase I Study to Investigate the Effect of BI 201335 Mediated UGT1A1 Inhibition on the Multiple Oral Dose Pharmacokinetics of Raltegravir (Isentress(R)) in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary) ; Raltegravir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record